Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
13.81
USD
|
0.00%
|
|
-1.22%
|
-23.74%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
806.1
|
486.5
|
942.5
|
1,085
|
833.1
|
-
|
-
|
Enterprise Value (EV)
1 |
806.1
|
486.5
|
621.3
|
600.5
|
452.9
|
440.3
|
519.8
|
P/E ratio
|
-11.7
x
|
-4.98
x
|
-6.57
x
|
-6.59
x
|
-4.04
x
|
-3.66
x
|
-3.59
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
19.3
x
|
64.3
x
|
97.3
x
|
687
x
|
539
x
|
132
x
|
228
x
|
EV / Revenue
|
19.3
x
|
64.3
x
|
64.1
x
|
380
x
|
293
x
|
69.9
x
|
142
x
|
EV / EBITDA
|
-
|
-
|
-4.96
x
|
-3.29
x
|
-2.13
x
|
-1.76
x
|
-1.7
x
|
EV / FCF
|
-20.8
x
|
-6.29
x
|
-6.45
x
|
-5.12
x
|
-3.19
x
|
-2.21
x
|
-2.22
x
|
FCF Yield
|
-4.81%
|
-15.9%
|
-15.5%
|
-19.5%
|
-31.4%
|
-45.2%
|
-45.1%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
35,480
|
36,039
|
48,759
|
59,896
|
60,326
|
-
|
-
|
Reference price
2 |
22.72
|
13.50
|
19.33
|
18.11
|
13.81
|
13.81
|
13.81
|
Announcement Date
|
3/16/21
|
2/28/22
|
3/9/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
41.82
|
7.572
|
9.685
|
1.58
|
1.545
|
6.298
|
3.658
|
EBITDA
1 |
-
|
-
|
-125.4
|
-182.3
|
-212.5
|
-250.1
|
-306.1
|
EBIT
1 |
-41.64
|
-19.99
|
-127.2
|
-184.1
|
-220.6
|
-251.3
|
-282.6
|
Operating Margin
|
-99.59%
|
-263.95%
|
-1,313.37%
|
-11,654.75%
|
-14,281.11%
|
-3,990.23%
|
-7,725.23%
|
Earnings before Tax (EBT)
1 |
-41.53
|
-19.71
|
-123.3
|
-161.3
|
-207.9
|
-249.8
|
-278.3
|
Net income
1 |
-41.53
|
-19.71
|
-123.3
|
-161.3
|
-208.2
|
-245.8
|
-274.7
|
Net margin
|
-99.32%
|
-260.35%
|
-1,273.32%
|
-10,211.14%
|
-13,479.99%
|
-3,902.04%
|
-7,510.67%
|
EPS
2 |
-1.950
|
-2.710
|
-2.940
|
-2.750
|
-3.415
|
-3.769
|
-3.844
|
Free Cash Flow
1 |
-38.8
|
-77.4
|
-96.39
|
-117.3
|
-142
|
-199.1
|
-234.6
|
FCF margin
|
-92.79%
|
-1,022.13%
|
-995.26%
|
-7,422.91%
|
-9,193.2%
|
-3,161.92%
|
-6,413.95%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/21
|
2/28/22
|
3/9/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
1.999
|
1.249
|
4.989
|
1.482
|
1.965
|
1.332
|
0.248
|
-
|
-
|
-
|
0.3662
|
0.3871
|
0.8871
|
0.5
|
0.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-51.88
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-24.6
|
-28.21
|
-29.64
|
-31.95
|
-37.4
|
-42.1
|
-47.33
|
-47.68
|
-47.04
|
-52.39
|
-53.82
|
-55.56
|
-56.5
|
-59.22
|
-61.32
|
Operating Margin
|
-1,230.57%
|
-2,258.69%
|
-594.15%
|
-2,155.67%
|
-1,903.31%
|
-3,160.29%
|
-19,083.87%
|
-
|
-
|
-
|
-14,695.2%
|
-14,354.47%
|
-6,369.6%
|
-11,843.2%
|
-12,264.4%
|
Earnings before Tax (EBT)
1 |
-24.53
|
-28.1
|
-29.55
|
-30.62
|
-35.06
|
-37.55
|
-41.19
|
-41.49
|
-41.11
|
-46.96
|
-51.84
|
-53.86
|
-55.55
|
-57.47
|
-59.78
|
Net income
1 |
-24.53
|
-28.1
|
-29.55
|
-30.62
|
-35.06
|
-37.55
|
-41.19
|
-41.49
|
-41.11
|
-46.96
|
-51.29
|
-53.36
|
-54.81
|
-57.47
|
-59.78
|
Net margin
|
-1,227.16%
|
-2,249.8%
|
-592.22%
|
-2,065.79%
|
-1,784.22%
|
-2,818.92%
|
-16,609.68%
|
-
|
-
|
-
|
-14,004.27%
|
-13,785.36%
|
-6,178.16%
|
-11,493.5%
|
-11,955.5%
|
EPS
2 |
-0.6800
|
-0.7800
|
-0.8200
|
-0.6500
|
-0.7200
|
-0.6700
|
-0.7000
|
-0.7000
|
-0.6900
|
-0.7800
|
-0.8554
|
-0.8871
|
-0.9147
|
-0.8633
|
-0.9000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/9/22
|
8/8/22
|
11/8/22
|
3/9/23
|
5/9/23
|
8/9/23
|
11/9/23
|
2/27/24
|
5/6/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
321
|
484
|
380
|
393
|
313
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-38.8
|
-77.4
|
-96.4
|
-117
|
-142
|
-199
|
-235
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-48.1%
|
-41%
|
-54.8%
|
-65.1%
|
-88.3%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-43.1%
|
-37.4%
|
-55.4%
|
-67.8%
|
-95.6%
|
Assets
1 |
-
|
-
|
285.9
|
431.4
|
376.2
|
362.5
|
287.4
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.53
|
1.95
|
1.76
|
0.92
|
1.8
|
2.37
|
2.48
|
Capex / Sales
|
3.66%
|
25.79%
|
18.17%
|
58.29%
|
116.53%
|
37.61%
|
67.8%
|
Announcement Date
|
3/16/21
|
2/28/22
|
3/9/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
13.81
USD Average target price
41.08
USD Spread / Average Target +197.49% Consensus |
1st Jan change
|
Capi.
|
---|
| -23.74% | 833M | | +30.38% | 684B | | +26.51% | 568B | | -4.36% | 361B | | +19.30% | 329B | | +3.73% | 284B | | +16.70% | 240B | | +8.78% | 208B | | -7.93% | 200B | | +7.68% | 166B |
Other Pharmaceuticals
|